{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:52:03Z","timestamp":1791417123062,"version":"4.3.3"},"reference-count":60,"publisher":"Georg Thieme Verlag KG","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Otsuka Korea Pharmaceutical"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antipsychotic-induced weight gain and metabolic disturbance are common in\n                        schizophrenia, but liability varies across agents. Aripiprazole has a\n                        relatively favorable metabolic profile, yet evidence on aripiprazole\n                        once-monthly, its long-acting injectable formulation, remains limited. We\n                        hypothesized that switching from a higher liability antipsychotic would\n                        yield a greater weight reduction than switching from a lower liability\n                        agent.<\/jats:p>\n                  <jats:p>This 16-week, prospective, open-label, multicenter study enrolled patients\n                        with stable schizophrenia. Participants were stratified by the metabolic\n                        liability of their prior oral antipsychotic (high vs. low). Participants\n                        received aripiprazole once-monthly 400 mg intramuscularly every 4 weeks,\n                        with cross-titration of the prior agent. Anthropometric and metabolic\n                        parameters were assessed every 4 weeks from baseline. Weight changes at week\n                        16 were the principal outcome, and all analyses were exploratory. Mixed\n                        models for repeated measures evaluated changes over time, adjusting for\n                        covariates.<\/jats:p>\n                  <jats:p>Among the 151 participants (100 low-risk and 51 high-risk participants),\n                        weight, body mass index, and waist circumference decreased significantly in\n                        the high-risk group only, and more high-risk patients reached clinically\n                        meaningful improvement. Most lipid and glycemic indices changed little,\n                        although low-density lipoprotein cholesterol and total cholesterol decreased\n                        in both groups. Psychiatric symptoms remained stable. In a subgroup switched\n                        from oral aripiprazole (n=73), anthropometric and metabolic\n                        parameters were all unchanged.<\/jats:p>\n                  <jats:p>In patients previously exposed to high-metabolic-risk antipsychotics,\n                        switching to aripiprazole once-monthly was associated with short-term\n                        reductions in weight and central adiposity\u2014consistent with the reversal of\n                        the prior agents' metabolic burden\u2014while psychiatric stability was\n                        maintained. Longer-term studies are needed to confirm their durability and\n                        clinical significance.<\/jats:p>","DOI":"10.1055\/a-2959-4334","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:30:57Z","timestamp":1791415857000},"source":"Crossref","is-referenced-by-count":0,"title":["Changes in Weight and Metabolic Indices after Switching to\n                    Aripiprazole Once-Monthly in Patients with Schizophrenia According to Prior Oral\n                    Antipsychotics"],"prefix":"10.1055","clinical-trial-number":[{"clinical-trial-number":"nct03376763","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Seoyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Korea (the Republic of)","place":["Seongnam-si"],"department":["Department of Neuropsychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Nowon Eulji University Hospital, Korea (the Republic of)","place":["Nowon-gu"],"department":["Department of Psychiatry"]},{"name":"Eulji University School of Medicine, Korea (the Republic of)","place":["Daejeon"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Seung","family":"Chee","sequence":"additional","affiliation":[{"name":"Chungnam National University Hospital, Korea (the Republic of)","place":["Daejeon"],"department":["Department of Psychiatry"]},{"name":"Chungnam National University, Korea (the Republic of)","place":["Yuseong-gu"],"department":["Brain Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonho","family":"Choi","sequence":"additional","affiliation":[{"name":"Hanyang University Guri Hospital, Korea (the Republic of)","place":["Guri-si"],"department":["Department of Psychiatry, Hanyang University College of\n                    Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Gongju National Hospital, Korea (the Republic of)","place":["Gongju-si"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Hyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Inha University Hospital, Korea (the Republic of)","place":["Incheon"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon-Jeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Korea University College of Medicine, Korea (the Republic of)","place":["Seongbuk-gu"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-2494","authenticated-orcid":false,"given":"Ji-Woon","family":"Jeong","sequence":"additional","affiliation":[{"name":"Pusan National University Yangsan\n                    Hospital, Korea (the Republic of)","place":["Yangsan-si"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Sang","family":"Lee","sequence":"additional","affiliation":[{"name":"Yong-In Mental Hospital, Korea (the Republic of)","place":["Yongin-si"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Ho","family":"Park","sequence":"additional","affiliation":[{"name":"Catholic Kwandong University International St Mary's\n                    Hospital, Korea (the Republic of)","place":["Incheon-si"],"department":["Department of Psychiatry and Behavioral Neurosciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Kyung Hee University College of Medicine, Korea (the Republic of)","place":["Dongdaemun-gu"],"department":["Department of Psychiatry, Kyung Hee University Hospital"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Seok","family":"Oh","sequence":"additional","affiliation":[{"name":"Konyang University Hospital, Korea (the Republic of)","place":["Daejeon"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Doo","family":"Kim","sequence":"additional","affiliation":[{"name":"Jeju National University Hospital, Korea (the Republic of)","place":["Jeju"],"department":["Department of Psychiatry, College of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-2331","authenticated-orcid":false,"given":"Euitae","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Korea (the Republic of)","place":["Seongnam-si"],"department":["Department of Neuropsychiatry"]},{"name":"Seoul National University, Korea (the Republic of)","place":["Gwanak-gu"],"department":["Department of Psychiatry, College of Medicine"]},{"name":"Seoul National University Medical Research Center, Korea (the Republic of)","place":["Jongno-gu"],"department":["Institute of Human Behavioral Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Soo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Seoul National University Medical Research\n                    Center, Korea (the Republic of)","place":["Jongno-gu"],"department":["Institute of Human Behavioral Science"]},{"name":"Hanyang University Hospital, Korea (the Republic of)","place":["Seoul"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"S R Marder","year":"2019","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"815456","DOI":"10.3389\/fnut.2021.815456","article-title":"Understanding the effects of antipsychotics on appetite control","volume":"8","author":"S Mukherjee","year":"2021","journal-title":"Front Nutr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on weight-gain caused by antipsychotics: a systematic review and\n                    meta-analysis","volume":"19","author":"B B Barton","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond\n                    weight gain","volume":"8","author":"D Grajales","year":"2019","journal-title":"Cells"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum\n                    disorders: baseline results from the RAISE-ETP study","volume":"71","author":"C U Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","article-title":"Association between cardiovascular risk factors and cognitive impairment in\n                    people with schizophrenia: a systematic review and meta-analysis","volume":"78","author":"K Hagi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/acps.13758","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a\n                    systematic review and meta-analysis","volume":"151","author":"R De","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0920-9964(02)00498-x","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"P J Weiden","year":"2004","journal-title":"Schizophr Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11920-023-01458-0","article-title":"Antipsychotic-induced weight gain in severe mental illness: risk factors and\n                    special considerations","volume":"25","author":"N Stogios","year":"2023","journal-title":"Curr Psychiatry Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00213-016-4324-8","article-title":"Atypical antipsychotics and effects on feeding: from mice to men","volume":"233","author":"L Benarroch","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5498\/wjp.v11.i10.696","article-title":"Metabolic disturbances associated with antipsychotic drug treatment in patients\n                    with schizophrenia: State-of-the-art and future perspectives","volume":"11","author":"S C Chang","year":"2021","journal-title":"World J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12888-022-03746-0","article-title":"Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the\n                    impact of high weight gain risk vs low weight gain risk treatment","volume":"22","author":"R Khandker","year":"2022","journal-title":"BMC Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable\n                    antipsychotics for the maintenance treatment of adults with schizophrenia: a\n                    systematic review and network meta-analysis","volume":"399","author":"J Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and\n                    novel treatment approaches based on pathophysiology","volume":"172","author":"S J Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3389\/fnins.2017.00643","article-title":"Molecular mechanisms of antipsychotic drug-induced diabetes","volume":"11","author":"J Chen","year":"2017","journal-title":"Front Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on\n                    treatment adherence","volume":"13","author":"M Dayabandara","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"T S Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","article-title":"Metabolic syndrome in psychiatric patients: overview, mechanisms, and\n                    implications","volume":"20","author":"BWJ H Penninx","year":"2018","journal-title":"Dialogues Clin Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust\n                    pharmacology","volume":"28","author":"D A Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1210\/en.2006-0418","article-title":"Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes\n                    and plasma des-acyl ghrelin levels in Ay mice","volume":"147","author":"K Nonogaki","year":"2006","journal-title":"Endocrinology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/13651501.2022.2151473","article-title":"Dopamine partial agonists: a discrete class of antipsychotics","volume":"27","author":"D Taylor","year":"2023","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from\n                    receptor-binding profiles","volume":"13","author":"H A Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41537-021-00158-z","article-title":"Efficacy and tolerability of aripiprazole versus D(2) antagonists in the early\n                    course of schizophrenia: a systematic review and meta-analysis","volume":"7","author":"D D Kim","year":"2021","journal-title":"NPJ Schizophr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","article-title":"Efficacy, acceptability and side-effects of oral versus long-acting- injectables\n                    antipsychotics: Systematic review and network meta-analysis","volume":"83","author":"D Wang","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41380-023-02175-z","article-title":"Real-world effectiveness of long-acting injectable antipsychotic treatments in a\n                    nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders","volume":"28","author":"L Boyer","year":"2023","journal-title":"Mol Psychiatry"},{"key":"ref26","first-page":"17","article-title":"Comparison of the peak-to-trough fluctuation in plasma concentration of\n                    long-acting injectable antipsychotics and their oral equivalents","volume":"9","author":"J J Sheehan","year":"2012","journal-title":"Innov Clin Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/NDT.S412357","article-title":"Aripiprazole plasma concentrations delivered from two 2-month long-acting\n                    injectable formulations: an indirect comparison","volume":"19","author":"M Harlin","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.pnpbp.2011.03.022","article-title":"The prevalence of metabolic syndrome in Korean patients with schizophrenia\n                    receiving a monotherapy with aripiprazole, olanzapine or risperidone","volume":"35","author":"N Y Lee","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and\n                    metabolic adverse effects in schizophrenia: a systematic review and\n                    meta-analysis","volume":"40","author":"Y Mizuno","year":"2014","journal-title":"Schizophr Bull"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fpsyt.2018.00744","article-title":"Metabolic syndrome in psychotic disorder patients treated with oral and\n                    long-acting injected antipsychotics","volume":"9","author":"A Ventriglio","year":"2018","journal-title":"Front Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine,\n                    quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison\n                    of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"T S Stroup","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2025.04.033","article-title":"Stability of psychotic symptoms and safety in switching to aripiprazole\n                    once-monthly according to prior oral antipsychotic drugs","volume":"281","author":"E Kim","year":"2025","journal-title":"Schizophr Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","article-title":"Blonanserin for schizophrenia: systematic review and meta-analysis of\n                    double-blind, randomized, controlled trials","volume":"47","author":"T Kishi","year":"2013","journal-title":"J Psychiatr Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7570\/jomes23031","article-title":"Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by\n                    the Korean Society for the study of obesity","volume":"32","author":"J H Haam","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.15616\/bsl.2017.23.4.348","article-title":"Triglyceride and glucose (TyG) index is a clinical surrogate marker for the\n                    diagnosis of metabolic syndrome","volume":"23","author":"K-A Shin","year":"2017","journal-title":"Biomed Sci Lett"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.numecd.2024.01.023","article-title":"Predictive cut-off values for the triglyceride-to-high-density lipoprotein\n                    cholesterol ratio to predict metabolic syndrome in the middle-aged Korean\n                    population","volume":"34","author":"J Y Kim","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pcn.12275","article-title":"Psychotropic dose equivalence in Japan","volume":"69","author":"T Inada","year":"2015","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose Equivalents for Antipsychotic Drugs: The DDD Method","volume":"42","author":"S Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/0049124106292364","article-title":"Advances in group-based trajectory modeling and an SAS procedure for estimating\n                    them","volume":"35","author":"B L Jones","year":"2007","journal-title":"Sociol Method Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/0269881111430748","article-title":"Comparative effectiveness of switching antipsychotic drug treatment to\n                    aripiprazole or ziprasidone for improving metabolic profile and atherogenic\n                    dyslipidemia: a 12-month, prospective, open-label study","volume":"26","author":"Y Chen","year":"2012","journal-title":"J Psychopharmacol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2019.052","article-title":"Stopping and switching antipsychotic drugs","volume":"42","author":"N Keks","year":"2019","journal-title":"Aust Prescr"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.schres.2018.11.031","article-title":"Weight gain and metabolic change as predictors of symptom improvement in\n                    first-episode schizophrenia spectrum disorder patients treated over\n                    12\u202fmonths","volume":"206","author":"H Luckhoff","year":"2019","journal-title":"Schizophr Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13469","article-title":"Therapeutic response is associated with antipsychotic-induced\n                    weight gain in drug-naive first-episode patients with schizophrenia: an 8-week\n                    prospective study","volume":"82","author":"Y Q Chen","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/cap.2018.0120","article-title":"Adiposity, hepatic triglyceride, and carotid intima media thickness during\n                    behavioral weight loss treatment in antipsychotic-treated youth: a randomized\n                    pilot study","volume":"29","author":"G E Nicol","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"577919","DOI":"10.3389\/fendo.2021.577919","article-title":"Reversibility of antipsychotic-induced weight gain: a systematic review and\n                    meta-analysis","volume":"12","author":"H Speyer","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-induced weight gain: dose-response meta-analysis of randomized\n                    controlled trials","volume":"48","author":"H Wu","year":"2022","journal-title":"Schizophr Bull"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4088\/JCP.22r14490","article-title":"Comparative effects of 11 antipsychotics on weight gain and metabolic function\n                    in patients with acute schizophrenia: a dose-response meta-analysis","author":"M Sab\u00e9","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12888-018-1889-2","article-title":"Hospital utilization rates following antipsychotic dose reductions: implications\n                    for tardive dyskinesia","volume":"18","author":"S N Caroff","year":"2018","journal-title":"BMC Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/schbul\/sbad089","article-title":"Long-acting injectable second-generation antipsychotics vs placebo and their\n                    oral formulations in acute schizophrenia: a systematic review and meta-analysis\n                    of randomized-controlled-trials","volume":"50","author":"D Wang","year":"2024","journal-title":"Schizophr Bull"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hup.1225","article-title":"Comparison of metabolic changes in patients with schizophrenia during randomized\n                    treatment with intramuscular olanzapine long-acting injection versus oral\n                    olanzapine","volume":"26","author":"D P McDonnell","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","article-title":"Effects of moderate and subsequent progressive weight loss on metabolic function\n                    and adipose tissue biology in humans with obesity","volume":"23","author":"F Magkos","year":"2016","journal-title":"Cell Metab"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"P Sumithran","year":"2011","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/ijo.2017.124","article-title":"Metabolite profiling of obese individuals before and after a one year weight\n                    loss program","volume":"41","author":"N Geidenstam","year":"2017","journal-title":"Int J Obes (Lond)"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with\n                    schizophrenia and other severe mental illnesses","volume":"2","author":"D C Henderson","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3803\/EnM.2020.301","article-title":"Metabolically healthy and unhealthy normal weight and obesity","volume":"35","author":"N Stefan","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the\n                    STEP 1 trial extension","volume":"24","author":"JP H Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/wps.20714","article-title":"Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment\n                    plus healthy lifestyle education in overweight or obese youth with severe mental\n                    illness: results from the IMPACT trial","volume":"19","author":"C U Correll","year":"2020","journal-title":"World Psychiatry"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.psychres.2016.11.044","article-title":"Clinical trial methodology to assess the efficacy\/effectiveness of long-acting\n                    antipsychotics: randomized controlled trials vs naturalistic studies","volume":"247","author":"A Fagiolini","year":"2017","journal-title":"Psychiatry Res"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/eip.12251","article-title":"Antipsychotic-induced weight gain in first-episode psychosis patients: a\n                    meta-analysis of differential effects of antipsychotic medications","volume":"10","author":"C Tek","year":"2016","journal-title":"Early Interv Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation\n                    antipsychotics in the treatment of schizophrenia: a systematic review and\n                    meta-analysis","volume":"123","author":"C Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2959-4334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:30:58Z","timestamp":1791415858000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2959-4334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":60,"URL":"https:\/\/doi.org\/10.1055\/a-2959-4334","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}